pdufa.bio

MFLUSIVA (Influenza Vaccine, mRNA / mRNA-1010)

Page updated ·next FDA decision on the calendar ·Data as of Nov 5, 2026 9:00 PM ET

MFLUSIVA (Influenza Vaccine, mRNA / mRNA-1010) is a Moderna Inc. program in seasonal influenza in U.S. adults 50 years of age and older. The FDA approved it on Aug 5, 2026. 1 FDA decision on record below. Every date links its source.

MRNA catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

FDA approval tracked on pdufa.bio: seasonal influenza in U.S. adults 50 years of age and older (approved Aug 5, 2026). Earlier approvals may not be listed here; the FDA label is the full record. Sponsor: Moderna Inc. (MRNA). Market-cap tier at the time we tracked it: Large. We track 1 catalyst event for this program: 0 upcoming and 1 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

PDUFA · Aug 5, 2026 ✓ ApprovedMRNA

Questions

When is MFLUSIVA (Influenza Vaccine, mRNA / mRNA-1010)'s next FDA decision or readout?

No upcoming catalyst is on our calendar for MFLUSIVA (Influenza Vaccine, mRNA / mRNA-1010); 1 FDA decision is on record below.

What happened at MFLUSIVA (Influenza Vaccine, mRNA / mRNA-1010)'s most recent FDA decision?

On Aug 5, 2026 the FDA approved the application. The decision page carries the source document and the measured share-price reaction.

What is MFLUSIVA (Influenza Vaccine, mRNA / mRNA-1010) used for?

In our records MFLUSIVA (Influenza Vaccine, mRNA / mRNA-1010) is FDA-approved for seasonal influenza in U.S. adults 50 years of age and older (approved Aug 5, 2026). Other approved uses may not be tracked here; the FDA label is the full record.

Who makes MFLUSIVA (Influenza Vaccine, mRNA / mRNA-1010)?

Moderna Inc. (MRNA).

Has MFLUSIVA (Influenza Vaccine, mRNA / mRNA-1010) been approved by the FDA?

Yes. The FDA approved an application for MFLUSIVA (Influenza Vaccine, mRNA / mRNA-1010) on Aug 5, 2026; the decision page linked above carries the source.

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.